On this call, we aim to understand how the FDA approval of the Allurion Balloon may influence the current obesity treatment paradigm, including its competitive positioning versus pharmacologic options (e.g., GLP-1s) and bariatric procedures, expected patient adoption, physician prescribing behavior, safety and efficacy perceptions, and the potential impact on market growth and treatment algorithms.